Troy Hinkley
Research Subjects
Troy Hinkley has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Jesse H. Erasmus
HDT Bio, Seattle, WA 98109, USA
5 shared publications - Carl Shaia
Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, USA
3 shared publications - David W. Hawman
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, USA
3 shared publications - Heinz Feldmann
National Institute of Allergy and Infectious Diseases
3 shared publications - Nikole L. Warner
HDT Bio, Seattle, USA
3 shared publications - Sam R. Nugen
Department of Food Science, Cornell University, Ithaca, NY, USA
3 shared publications
Latest Publications
- Open Access
- 12 November 2025
- Published by Springer Nature in Research Square
A localizing replicon RNA vaccine harnesses the intramuscular immune microenvironment to drive adaptive responses
Intramuscular administration of self-amplifying replicon RNA (repRNA) formulated with the cationic nanocarrier LION™ represents a promising strategy for inducing durable protective immunity with minimal doses and limited systemic reactogenicity. However, the cellular and molecular mechanisms by which it elicits adaptive immune responses remain incompletely understood. Here, we demonstrate that repRNA delivery generates a microenvironment within skeletal muscle that promotes adaptive immune responses. In this local environment, repRNA-transfected muscle cells transfer antigen-encoding RNA and proteins to antigen-presenting cells to cross-prime CD8⁺ T cells, while CD4⁺ T cells and CD138⁺ cells expand in parallel with antibody production. CD4⁺ T cells are required for humoral immunity, and intramuscular CD138⁺ cell frequencies correlate with serum antibody levels. These findings reveal a coordinated mechanism by which the muscle microenvironment orchestrates adaptive immunity following localized repRNA delivery and provide mechanistic insight for the rational design of next-generation RNA vaccines and therapeutics.
- 12 November 2025
- Published by Springer Nature in Research Square
Open AccessA localizing replicon RNA vaccine harnesses the intramuscular immune microenvironment to drive adaptive responses
Intramuscular administration of self-amplifying replicon RNA (repRNA) formulated with the cationic nanocarrier LION™ represents a promising strategy for inducing durable protective immunity with minimal doses and limited systemic reactogenicity. However, the cellular and molecular mechanisms by which it elicits adaptive immune responses remain incompletely understood. Here, we demonstrate that repRNA delivery generates a microenvironment within skeletal muscle that promotes adaptive immune responses. In this local environment, repRNA-transfected muscle cells transfer antigen-encoding RNA and proteins to antigen-presenting cells to cross-prime CD8⁺ T cells, while CD4⁺ T cells and CD138⁺ cells expand in parallel with antibody production. CD4⁺ T cells are required for humoral immunity, and intramuscular CD138⁺ cell frequencies correlate with serum antibody levels. These findings reveal a coordinated mechanism by which the muscle microenvironment orchestrates adaptive immunity following localized repRNA delivery and provide mechanistic insight for the rational design of next-generation RNA vaccines and therapeutics.
- 8 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (819) , eadw4646
A replicating RNA vaccine protects cynomolgus macaques against lethal clade 2.3.4.4b influenza A H5N1 virus challenge
In early 2024, clade 2.3.4.4b highly pathogenic avian influenza (HPAI) A H5N1 virus was detected in United States dairy cattle. Although so far the public health threat of contemporary clade 2.3.4.4b H5N1 virus strains remains low, continued circulation in mammals and frequent spillover into humans poses a threat of pandemic H5N1. The United States and other countries have stockpiled vaccines and have plans in place to rapidly produce additional vaccine doses should a pandemic H5N1 virus emerge. However, the continued antigenic drift of clade 2.3.4.4b H5N1 antigens compared with historical antigens used by stockpiled vaccines has raised questions of whether these vaccines will confer protection or whether stockpiles need to be updated. We recently evaluated a replicating RNA (repRNA) vaccine against lethal contemporary 2.3.4.4b H5N1 virus challenge in mice and found that a homologous, but not historical, H5 hemagglutinin (HA)–based vaccine conferred protection. Here, we further evaluated the protective capacity of a repRNA expressing the contemporary 2.3.4.4b HA or a repRNA expressing a historical H5 HA (A/Vietnam/1203/2004) in a recently developed lethal nonhuman primate (NHP) challenge model. We found that both vaccines conferred robust protection against lethal 2.3.4.4b H5N1 virus challenge, reducing viral loads and signs of respiratory illness. Our data show that the repRNA platform can elicit protective immunity against lethal influenza virus challenge in NHPs and that historical H5 HAs can elicit cross-protective immunity.
- 8 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (819) , eadw4646
A replicating RNA vaccine protects cynomolgus macaques against lethal clade 2.3.4.4b influenza A H5N1 virus challenge
In early 2024, clade 2.3.4.4b highly pathogenic avian influenza (HPAI) A H5N1 virus was detected in United States dairy cattle. Although so far the public health threat of contemporary clade 2.3.4.4b H5N1 virus strains remains low, continued circulation in mammals and frequent spillover into humans poses a threat of pandemic H5N1. The United States and other countries have stockpiled vaccines and have plans in place to rapidly produce additional vaccine doses should a pandemic H5N1 virus emerge. However, the continued antigenic drift of clade 2.3.4.4b H5N1 antigens compared with historical antigens used by stockpiled vaccines has raised questions of whether these vaccines will confer protection or whether stockpiles need to be updated. We recently evaluated a replicating RNA (repRNA) vaccine against lethal contemporary 2.3.4.4b H5N1 virus challenge in mice and found that a homologous, but not historical, H5 hemagglutinin (HA)–based vaccine conferred protection. Here, we further evaluated the protective capacity of a repRNA expressing the contemporary 2.3.4.4b HA or a repRNA expressing a historical H5 HA (A/Vietnam/1203/2004) in a recently developed lethal nonhuman primate (NHP) challenge model. We found that both vaccines conferred robust protection against lethal 2.3.4.4b H5N1 virus challenge, reducing viral loads and signs of respiratory illness. Our data show that the repRNA platform can elicit protective immunity against lethal influenza virus challenge in NHPs and that historical H5 HAs can elicit cross-protective immunity.
- Open Access
- 6 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-9
Single-dose replicon RNA Sudan virus vaccine uniformly protects female guinea pigs from disease
The Sudan virus (SUDV) outbreaks in Uganda in 2022 and 2025 created public health concerns in-country and the entire East African region. There are currently no licensed countermeasures against SUDV. We developed a SUDV vaccine candidate based on a nanocarrier (LIONTM) complexed with an alphavirus-based replicon RNA. Here, we compare the protective efficacy of the LION-SUDV vaccine either encoding the SUDV glycoprotein (GP) alone or in combination with the Ebola virus (EBOV) GP (LION-Combination). A LION-EBOV vaccine which is protective against EBOV was also included to determine the potential for cross-protection against SUDV infection. Single-dose vaccinations were conducted three weeks before challenge with a lethal dose of guinea pig-adapted SUDV using a female guinea pig disease model. We demonstrate 100% survival and protection with the LION-SUDV and the LION-Combination vaccines, while the LION-EBOV vaccine achieved 50% protection. Antigen-specific humoral responses correlate with decreased virus replication and survival. This result warrants further studies in larger animal species to ensure that protective efficacy is maintained with the single-dose LION-SUDV vaccine.
- 6 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-9
Open AccessSingle-dose replicon RNA Sudan virus vaccine uniformly protects female guinea pigs from disease
The Sudan virus (SUDV) outbreaks in Uganda in 2022 and 2025 created public health concerns in-country and the entire East African region. There are currently no licensed countermeasures against SUDV. We developed a SUDV vaccine candidate based on a nanocarrier (LIONTM) complexed with an alphavirus-based replicon RNA. Here, we compare the protective efficacy of the LION-SUDV vaccine either encoding the SUDV glycoprotein (GP) alone or in combination with the Ebola virus (EBOV) GP (LION-Combination). A LION-EBOV vaccine which is protective against EBOV was also included to determine the potential for cross-protection against SUDV infection. Single-dose vaccinations were conducted three weeks before challenge with a lethal dose of guinea pig-adapted SUDV using a female guinea pig disease model. We demonstrate 100% survival and protection with the LION-SUDV and the LION-Combination vaccines, while the LION-EBOV vaccine achieved 50% protection. Antigen-specific humoral responses correlate with decreased virus replication and survival. This result warrants further studies in larger animal species to ensure that protective efficacy is maintained with the single-dose LION-SUDV vaccine.
- Open Access
- 25 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Antibodies targeting the Crimean-Congo Hemorrhagic Fever Virus nucleoprotein protect via TRIM21
Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a negative-sense RNA virus spread by Hyalomma genus ticks across Europe, Asia, and Africa. CCHF disease begins as a non-specific febrile illness which may progress into a severe hemorrhagic disease with no widely approved or highly efficacious interventions currently available. Recently, we reported a self-replicating, alphavirus-based RNA vaccine that expresses the CCHFV nucleoprotein and is protective against lethal CCHFV disease in mice. This vaccine induces high titers of non-neutralizing anti-NP antibodies and we show here that protection does not require Fc-gamma receptors or complement. Instead, vaccinated mice deficient in the intracellular Fc-receptor TRIM21 were unable to control the infection despite mounting robust CCHFV-specific immunity. We also show that passive transfer of NP-immune sera confers significant TRIM21-dependent protection against lethal CCHFV challenge. Together our data identifies TRIM21-mediated mechanisms as the Fc effector function of protective antibodies against the CCHFV NP and provides mechanistic insight into how vaccines against the CCHFV NP confer protection.
- 25 October 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Open AccessAntibodies targeting the Crimean-Congo Hemorrhagic Fever Virus nucleoprotein protect via TRIM21
Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a negative-sense RNA virus spread by Hyalomma genus ticks across Europe, Asia, and Africa. CCHF disease begins as a non-specific febrile illness which may progress into a severe hemorrhagic disease with no widely approved or highly efficacious interventions currently available. Recently, we reported a self-replicating, alphavirus-based RNA vaccine that expresses the CCHFV nucleoprotein and is protective against lethal CCHFV disease in mice. This vaccine induces high titers of non-neutralizing anti-NP antibodies and we show here that protection does not require Fc-gamma receptors or complement. Instead, vaccinated mice deficient in the intracellular Fc-receptor TRIM21 were unable to control the infection despite mounting robust CCHFV-specific immunity. We also show that passive transfer of NP-immune sera confers significant TRIM21-dependent protection against lethal CCHFV challenge. Together our data identifies TRIM21-mediated mechanisms as the Fc effector function of protective antibodies against the CCHFV NP and provides mechanistic insight into how vaccines against the CCHFV NP confer protection.
- Open Access
- 26 June 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-16
A gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge
Epstein-Barr virus (EBV) is associated with several malignancies, neurodegenerative disorders and is the causative agent of infectious mononucleosis. A vaccine that prevents EBV-driven morbidity and mortality remains an unmet need. EBV is orally transmitted, infecting both B cells and epithelial cells. Several virally encoded proteins are involved in entry. The gH/gL glycoprotein complex is essential for infectivity irrespective of cell type, while gp42 is essential for infection of B cells. gp350 promotes viral attachment by binding to CD21 or CD35 and is the most abundant glycoprotein on the virion. gH/gL, gp42 and gp350, are known targets of neutralizing antibodies and therefore relevant immunogens for vaccine development. Here, we developed and optimized the delivery of several alphavirus-derived replicon RNA (repRNA) vaccine candidates encoding gH/gL, gH/gL/gp42 or gp350 delivered by a cationic nanocarrier termed LION™. The lead candidate, encoding full-length gH/gL, elicited high titers of neutralizing antibodies that persisted for at least 8 months and a vaccine-specific CD8+ T cell response. Transfer of vaccine-elicited IgG protected humanized mice from EBV-driven tumor formation and death following high-dose viral challenge. These data demonstrate that LION/repRNA-gH/gL is an ideal candidate vaccine for preventing EBV infection and/or related malignancies in humans.
- 26 June 2024
- Published by Springer Nature in npj Vaccines
- Vol. 9 (1) , 1-16
Open AccessA gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge
Epstein-Barr virus (EBV) is associated with several malignancies, neurodegenerative disorders and is the causative agent of infectious mononucleosis. A vaccine that prevents EBV-driven morbidity and mortality remains an unmet need. EBV is orally transmitted, infecting both B cells and epithelial cells. Several virally encoded proteins are involved in entry. The gH/gL glycoprotein complex is essential for infectivity irrespective of cell type, while gp42 is essential for infection of B cells. gp350 promotes viral attachment by binding to CD21 or CD35 and is the most abundant glycoprotein on the virion. gH/gL, gp42 and gp350, are known targets of neutralizing antibodies and therefore relevant immunogens for vaccine development. Here, we developed and optimized the delivery of several alphavirus-derived replicon RNA (repRNA) vaccine candidates encoding gH/gL, gH/gL/gp42 or gp350 delivered by a cationic nanocarrier termed LION™. The lead candidate, encoding full-length gH/gL, elicited high titers of neutralizing antibodies that persisted for at least 8 months and a vaccine-specific CD8+ T cell response. Transfer of vaccine-elicited IgG protected humanized mice from EBV-driven tumor formation and death following high-dose viral challenge. These data demonstrate that LION/repRNA-gH/gL is an ideal candidate vaccine for preventing EBV infection and/or related malignancies in humans.
- Open Access
- 15 February 2024
- Published by Springer Nature in Research Square
Antibodies Targeting the CCHFV Nucleocapsid Protein Require TRIM21 for Protection
Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a negative-sense RNA virus spread by Hyalomma genus ticks across Europe, Asia, and Africa. CCHF disease begins as a non-specific febrile illness which may progress into a severe hemorrhagic disease and there are currently no widely approved or highly efficacious interventions available. Recently, we reported a self-replicating, alphavirus-based RNA vaccine which expresses the CCHFV nucleoprotein and is protective against lethal CCHFV disease in mice. This vaccine induces high titers of non-neutralizing anti-NP antibodies and is protective even in mice with constitutive knock-out of Fc-gamma receptors or complement, indicating these mechanisms are not required for protection. Instead, vaccinated mice deficient in the intracellular Fc-receptor TRIM21 despite having robust CCHFV-specific immunity, were unable to control the infection. We also show that passive transfer of NP-immune sera confers significant and TRIM21-dependent protection against lethal CCHFV challenge. Together our data identifies TRIM21 as the Fc effector function of protective antibodies against the CCHFV NP and provides mechanistic insight into how vaccines against CCHFV confer protection.
- 15 February 2024
- Published by Springer Nature in Research Square
Open AccessAntibodies Targeting the CCHFV Nucleocapsid Protein Require TRIM21 for Protection
Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a negative-sense RNA virus spread by Hyalomma genus ticks across Europe, Asia, and Africa. CCHF disease begins as a non-specific febrile illness which may progress into a severe hemorrhagic disease and there are currently no widely approved or highly efficacious interventions available. Recently, we reported a self-replicating, alphavirus-based RNA vaccine which expresses the CCHFV nucleoprotein and is protective against lethal CCHFV disease in mice. This vaccine induces high titers of non-neutralizing anti-NP antibodies and is protective even in mice with constitutive knock-out of Fc-gamma receptors or complement, indicating these mechanisms are not required for protection. Instead, vaccinated mice deficient in the intracellular Fc-receptor TRIM21 despite having robust CCHFV-specific immunity, were unable to control the infection. We also show that passive transfer of NP-immune sera confers significant and TRIM21-dependent protection against lethal CCHFV challenge. Together our data identifies TRIM21 as the Fc effector function of protective antibodies against the CCHFV NP and provides mechanistic insight into how vaccines against CCHFV confer protection.
- Open Access
- 28 January 2022
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 22 (11) , 2155-2164
A microfluidic device and instrument prototypes for the detection of Escherichia coli in water samples using a phage-based bioluminescence assay
A phage-based microfluidic platform for highly sensitive and rapid detection of E. coli in low-resource settings.
- 28 January 2022
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 22 (11) , 2155-2164
Open AccessA microfluidic device and instrument prototypes for the detection of Escherichia coli in water samples using a phage-based bioluminescence assay
A phage-based microfluidic platform for highly sensitive and rapid detection of E. coli in low-resource settings.
- 1 March 2021
- Published by Elsevier in Food and Bioproducts Processing
- Vol. 126, 207-214
Recombinant lactase with a cellulose binding domain permits facile immobilization onto cellulose with retained activity
- 1 March 2021
- Published by Elsevier in Food and Bioproducts Processing
- Vol. 126, 207-214
Recombinant lactase with a cellulose binding domain permits facile immobilization onto cellulose with retained activity
- 13 December 2018
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 144 (4) , 1345-1352
Phage based electrochemical detection of Escherichia coli in drinking water using affinity reporter probes
The monitoring of drinking water for indicators of fecal contamination is crucial for ensuring a safe supply. In this study, a novel electrochemical method was developed for the rapid and sensitive detection of Escherichia coli (E. coli) in drinking water. This strategy is based on the use of engineered bacteriophages (phages) to separate and concentrate target E. coli when conjugated with magnetic beads, and to facilitate the detection by expressing gold binding peptides fused alkaline phosphatase (GBPs-ALP). The fusion protein GBPs-ALP has both the enzymatic activity and the ability to directly bind onto a gold surface. This binding-peptide mediated immobilization method provided a novel and simple approach to immobilize proteins on a solid surface, requiring no post-translational modifications. The concentration of E. coli was determined by measuring the activity of the ALP on gold electrodes electrochemically using linear sweep voltammetry (LSV). This approach was successfully applied in the detection of E. coli in drinking water. We were able to detect 105 CFU mL−1 of E. coli within 4 hours. After 9 hours of preincubation, 1 CFU of E. coli in 100 mL of drinking water was detected with a total assay time of 12 hours. This approach compares favorably to the current EPA method and has the potential to be applied to detect different bacteria in other food matrices.
- 13 December 2018
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 144 (4) , 1345-1352
Phage based electrochemical detection of Escherichia coli in drinking water using affinity reporter probes
The monitoring of drinking water for indicators of fecal contamination is crucial for ensuring a safe supply. In this study, a novel electrochemical method was developed for the rapid and sensitive detection of Escherichia coli (E. coli) in drinking water. This strategy is based on the use of engineered bacteriophages (phages) to separate and concentrate target E. coli when conjugated with magnetic beads, and to facilitate the detection by expressing gold binding peptides fused alkaline phosphatase (GBPs-ALP). The fusion protein GBPs-ALP has both the enzymatic activity and the ability to directly bind onto a gold surface. This binding-peptide mediated immobilization method provided a novel and simple approach to immobilize proteins on a solid surface, requiring no post-translational modifications. The concentration of E. coli was determined by measuring the activity of the ALP on gold electrodes electrochemically using linear sweep voltammetry (LSV). This approach was successfully applied in the detection of E. coli in drinking water. We were able to detect 105 CFU mL−1 of E. coli within 4 hours. After 9 hours of preincubation, 1 CFU of E. coli in 100 mL of drinking water was detected with a total assay time of 12 hours. This approach compares favorably to the current EPA method and has the potential to be applied to detect different bacteria in other food matrices.
- Open Access
- 2 August 2018
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 143 (17) , 4074-4082
Reporter bacteriophage T7 NLC utilizes a novel NanoLuc::CBM fusion for the ultrasensitive detection of Escherichia coli in water
Rapid detection of bacteria responsible for foodborne diseases is a growing necessity for public health. Reporter bacteriophages (phages) are robust biorecognition elements uniquely suited for the rapid and sensitive detection of bacterial species. The advantages of phages include their host specificity, ability to distinguish viable and non-viable cells, low cost, and ease of genetic engineering. Upon infection with reporter phages, target bacteria express reporter enzymes encoded within the phage genome. In this study, the T7 coliphage was genetically engineered to express the newly developed luceriferase, NanoLuc (NLuc), as an indicator of bacterial contamination. While several genetic approaches were employed to optimize reporter enzyme expression, the novel achievement of this work was the successful fusion of the NanoLuc reporter to a carbohydrate binding module (CBM) with specificity to crystalline cellulose. This novel chimeric reporter (nluc::cbm) bestows the specific and irreversible immobilization of NanoLuc onto a low-cost, widely available crystalline cellulosic substrate. We have shown the possibility of detecting the immobilized fusion protein in a filter plate which resulted from a single CFU of E. coli. We then demonstrated that microcrystalline cellulose can be used to concentrate the fusion reporter from 100 mL water samples allowing a limit of detection of −1E. coli in 3 hours. Therefore, we conclude that our phage-based detection assay displays significant aptitude as a proof-of-concept drinking water diagnostic assay for the low-cost, rapid and sensitive detection of E. coli. Additional improvements in the capture efficiency of the phage-based fusion reporter should allow a limit of detection of <10 CFU per 100 mL.
- 2 August 2018
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 143 (17) , 4074-4082
Open AccessReporter bacteriophage T7 NLC utilizes a novel NanoLuc::CBM fusion for the ultrasensitive detection of Escherichia coli in water
Rapid detection of bacteria responsible for foodborne diseases is a growing necessity for public health. Reporter bacteriophages (phages) are robust biorecognition elements uniquely suited for the rapid and sensitive detection of bacterial species. The advantages of phages include their host specificity, ability to distinguish viable and non-viable cells, low cost, and ease of genetic engineering. Upon infection with reporter phages, target bacteria express reporter enzymes encoded within the phage genome. In this study, the T7 coliphage was genetically engineered to express the newly developed luceriferase, NanoLuc (NLuc), as an indicator of bacterial contamination. While several genetic approaches were employed to optimize reporter enzyme expression, the novel achievement of this work was the successful fusion of the NanoLuc reporter to a carbohydrate binding module (CBM) with specificity to crystalline cellulose. This novel chimeric reporter (nluc::cbm) bestows the specific and irreversible immobilization of NanoLuc onto a low-cost, widely available crystalline cellulosic substrate. We have shown the possibility of detecting the immobilized fusion protein in a filter plate which resulted from a single CFU of E. coli. We then demonstrated that microcrystalline cellulose can be used to concentrate the fusion reporter from 100 mL water samples allowing a limit of detection of −1E. coli in 3 hours. Therefore, we conclude that our phage-based detection assay displays significant aptitude as a proof-of-concept drinking water diagnostic assay for the low-cost, rapid and sensitive detection of E. coli. Additional improvements in the capture efficiency of the phage-based fusion reporter should allow a limit of detection of <10 CFU per 100 mL.